SRR1329885
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.505
- INFLAMMATORY_RESPONSE+0.492
- IL6_JAK_STAT3_SIGNALING+0.488
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.481
- ALLOGRAFT_REJECTION+0.471
- TNFA_SIGNALING_VIA_NFKB+0.424
- INTERFERON_GAMMA_RESPONSE+0.407
- KRAS_SIGNALING_UP+0.394
- COAGULATION+0.383
- INTERFERON_ALPHA_RESPONSE+0.383
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.670
- DNA_REPAIR-0.534
- MYC_TARGETS_V2-0.497
- MYC_TARGETS_V1-0.489
- MITOTIC_SPINDLE-0.381
- G2M_CHECKPOINT-0.379
- PROTEIN_SECRETION-0.371
- E2F_TARGETS-0.347
- ADIPOGENESIS-0.319
- UNFOLDED_PROTEIN_RESPONSE-0.297
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR818469 | GTEX | — | 0.955 |
| 2 | SRR600724 | GTEX | — | 0.955 |
| 3 | SRR1444932 | GTEX | — | 0.953 |
| 4 | BS_ZTWGFWTX | pilocytic astrocytoma | — | 0.953 |
| 5 | SRR1084484 | GTEX | — | 0.949 |
| 6 | SRR1323536 | GTEX | — | 0.947 |
| 7 | sclc55A_S50.txt | — | cohortMD2 | 0.947 |
| 8 | sclcA055A_S52.txt | — | cohortMD2 | 0.947 |
| 9 | SRR1071289 | GTEX | — | 0.946 |
| 10 | SRR1408327 | GTEX | — | 0.942 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.505 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.492 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.488 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.481 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.471 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.424 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.407 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.394 | Inavolisib | — uncovered |
| COAGULATION | 0.383 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.383 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.373 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.358 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.356 | Idelalisib | — uncovered |
| COMPLEMENT | 0.354 | Inavolisib | — uncovered |
| APOPTOSIS | 0.309 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.288 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.276 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.273 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.226 | Idelalisib | — uncovered |
| HYPOXIA | 0.215 | Idelalisib | — uncovered |